Personalized exercise may boost radiation outcomes in prostate cancer
NCT ID NCT04556045
First seen Jun 25, 2026 · Last updated Sep 18, 2026 · Updated 3 times
Summary
This study tests whether a personalized 4-week exercise program can improve quality of life and physical function in men with metastatic prostate cancer who are receiving radiation therapy. Eighty participants will either exercise or not, and researchers will track changes in well-being, inflammation, and survival. The goal is to see if adding exercise to standard care makes a real difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- personalized exercise therapy
- What this could lead to
- If it works, this could show that adding exercise to radiation improves quality of life and physical function, and may even help men live longer.
- What could go wrong
- This is a small, early-stage study (80 participants) without a placebo control. The exercise program is short (4 weeks), so benefits may be modest or not last. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
21 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
May 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Subjects must have lymph node positive or metastatic disease consistent with prostate cancer * Males ≥18 years of age receiving RT * Patient receiving 5 fractions or stereotactic body radiation therapy (SBRT) * Patient may have received prior hormone therapy. Prior or current use of chemotherapy agents is allowed, but not necessary. * Fluent in written and spoken English * Must be able to provide and understand informed consent * Must have an ECOG Performance Status (PS) of ≤ 3 * Primary attending radiation oncologist approval Exclusion Criteria: * Performing \> 90 minutes/week of exercise therapy prior at time of enrollment * Evidence in the medical record of an absolute contraindication for exercise * Cardiac exclusion criteria: * Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system * History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy * Uncontrolled arrhythmias; patients with rate-controlled atrial fibrillation for \>1 month prior to start of radiation therapy may be eligible * syncope * acute myocarditis, pericarditis, or endocarditis * acute pulmonary embolus or pulmonary infarction * thrombosis of lower extremities * suspected dissecting aneurysm * pulmonary edema * respiratory failure * acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise * Mental impairment leading to inability to complete study requirements * In-patient receiving radiation therapy for a radiation emergency (e.g. cord compression, Superior vena cava (SVC) syndrome, brain metastases) * High risk of fracture or spine instability (Mirels score ≥7, SINS ≥7) * Children (the protocol will only include men age 18 and older)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malignant neoplasm of prostate are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New antibody aims to preserve immune checkpoint while fighting cancer
- Two-Drug combo targets prostate cancer that outsmarts hormone therapy
- AI chatbot may calm nerves after a prostate cancer diagnosis
- Can a common diabetes drug slow prostate cancer progression?
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?